However, many NSCLC patients eventually became resistant to alectinib and one common mechanism of acquired resistance to ALK TKIs is the secretion of HGF into the tumor microenvironment, leading to HGF-dependent c-Met signaling [89]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.